Shopping Cart
- Remove All
- Your shopping cart is currently empty
Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants. |
In vitro | MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN).[1] |
In vivo | MOR202 (12 mg/kg; murine MM models) dose-dependently reduced osteolysis by up to 55%. Coadministration with 0.6 mg/kg BOR or 50 mg/kg LEN completely eliminated osteolysis at a low dose of 3 mg/kg.[1] |
Alias | TJ-202, MOR-202, MOR-03087 |
Molecular Weight | 143.65 kDa |
Cas No. | 2197112-39-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.